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Introduction
There are an estimated 1 million cases of  childhood tuberculosis (TB) each year and in 2015, 210,000 
children died of  TB (1). Children with TB are difficult to diagnose and treat and are at risk of  severe 
disease (2). The need for improved strategies to control childhood TB has led to studies to identify risk 
factors for TB disease in children. The longitudinal data collected during infant TB vaccine efficacy trials 
in South Africa with the vaccines Bacille Calmette-Guérin (BCG) and Modified Vaccinia Virus Ankara 
expressing Antigen 85A (MVA85A) (3, 4) have enabled the identification of  correlates of  TB disease risk 
in infants (5, 6). Using samples collected from 4- to 6-month-old infants at enrollment into the MVA85A 
efficacy trial in the Western Cape Province of  South Africa (4), we reported that CD4+ T cell activation 
(measured as HLA-DR expression) was associated with increased risk of  TB disease over the following 
3 years of  life (6). This finding was validated in an independent cohort of  Mycobacterium tuberculosis–
infected (M.tb–infected) adolescents (6). The consequences of  chronic T cell activation have not been 
previously explored in the context of  TB but are well described in HIV and include risk of  acquisition 
of  infection and disease progression in children (7–10) and adults (11–15). Recognition that T cell acti-
vation is a feature of  HIV immunopathogenesis is guiding the development of  new interventions for 
the management of  HIV, such as the use of  statins or Maraviroc as an adjunct to antiretroviral therapy 
(ART) or switching ART regimens (16–18).
Immune activation is associated with increased risk of tuberculosis (TB) disease in infants. We 
performed a case-control analysis to identify drivers of immune activation and disease risk. Among 
49 infants who developed TB disease over the first 2 years of life, and 129 healthy matched controls, 
we found the cytomegalovirus-stimulated (CMV-stimulated) IFN-γ response to be associated 
with CD8+ T cell activation (Spearman’s rho, P = 6 × 10–8). A CMV-specific IFN-γ response was also 
associated with increased risk of developing TB disease (conditional logistic regression; P = 0.043; 
OR, 2.2; 95% CI, 1.02–4.83) and shorter time to TB diagnosis (Log Rank Mantel-Cox, P = 0.037). 
CMV+ infants who developed TB disease had lower expression of NK cell–associated gene signatures 
and a lower frequency of CD3–CD4–CD8– lymphocytes. We identified transcriptional signatures 
predictive of TB disease risk among CMV ELISpot–positive (area under the receiver operating 
characteristic [AUROC], 0.98, accuracy, 92.57%) and –negative (AUROC, 0.9; accuracy, 79.3%) 
infants; the CMV– signature was validated in an independent infant study (AUROC, 0.71; accuracy, 
63.9%). A 16-gene signature that previously identified adolescents at risk of developing TB disease 
did not accurately classify case and control infants in this study. Understanding the microbial 
drivers of T cell activation, such as CMV, could guide new strategies for prevention of TB disease in 
infants.
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Sustained T cell activation and dysfunction of  antigen specific T cells can result from chronic exposure 
to antigen from persistent viral or bacterial infections (19). Human cytomegalovirus (CMV) and Epstein-
Barr virus (EBV) are known drivers of  T cell activation (12, 15), and CMV prevalence is high in developing 
countries — in particular, sub-Saharan Africa, where 85% of  infants are infected by 12 months of  age 
(reviewed in ref. 20). Recent epidemiological evidence supports a role for CMV in the etiology of  TB with 
notable similarity in the age-sex distribution between the 2 infections (21). Rates of  CMV infection were 
higher among TB patients than healthy volunteers in studies of  both Nigerian adults and Russian children 
and adolescents (22, 23). In a rural Ugandan cohort, higher CMV exposure (measured by CMV IgG levels) 
was associated with active TB disease and lower levels of  anti-mycobacterial antibodies (24, 25).
We previously reported that CD4+ T cell activation in infants and adolescents was associated with 
increased risk of  developing TB disease (6). Here, we aimed to understand the drivers of  this immune 
activation in the infant population — specifically whether viral infection with CMV or EBV may play a 
role. We used transcriptional analysis to further explore the pathways associated with immune activation 
and viral infection. Improved understanding of  the causes and impact of  T cell activation could transform 
future approaches to protect against TB, including the use of  vaccines, antibiotics, or antivirals, as well as 
protective behaviors to reduce the burden of  chronic microbial drivers.
Results
Activated CD8+ T cells are associated with TB disease risk and correlate with CMV-specific IFN-γ response. Infants 
who were enrolled in an efficacy trial of  the candidate TB vaccine MVA85A were included in this study (4) 
(Figure 1). All infants received BCG within 7 days of  birth. Infants were screened at 4–6 months of  age, 
and only those with clinical parameters within the normal range who were HIV- and M.tb–uninfected and 
without known TB exposure were included in the trial. CMV and EBV analysis were conducted on a blood 
Figure 1. Study design for immune correlates analysis. Infants who were enrolled in an efficacy trial of the candidate 
TB vaccine MVA85A were included in this study (4). Infants were randomized at 16–24 weeks of age to receive a single 
intradermal dose of MVA85A or placebo (Candin, a candida skin test antigen) (4). Boxes indicate the number of case 
infant (red) or control infant (gray) samples available for combined Day 0 (D0) and D28 analysis. Analysis was restricted 
to infants where a frozen PBMC sample was available and live cells in PBMC were > 50% (or PHA IFN-γ ELISPOT ≥ 1000 
SFC/million), as well as to infants where a sample was available for analysis from both the D0 and D28 time points. 
Control infants were excluded if the corresponding matched case was not in the analysis. QFT, QuantiFERON-TB Gold 
test; HH, household. 
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sample taken at this time point. Infants were randomized to receive a single intradermal dose of  MVA85A 
or placebo (Candin, a candida skin test antigen) (4). In contrast to our previous analysis, which focused on 
the sample collected at enrollment (day 0; D0), samples collected from 2 time points, D0 and D28 following 
MVA85A or placebo were combined for testing of  both cellular parameters and transcriptional signatures 
associated with risk of  TB disease. We have shown that the correlates of  risk measured in our previous 
study were not affected by intervention (MVA85A or placebo) (6). Only infants for whom a sample was 
available at both D0 and D28 were included in the analysis (Figure 1).
Previously, we identified an association between TB disease risk over the first 2 years of life and the frequen-
cy of activated HLA-DR+CD4+ T cells at age 4–6 months (6). We also found that the magnitude of BCG-spe-
cific IFN-γ–expressing cells and levels of anti–Ag85A IgG were associated with reduced risk of TB disease (6). 
In our present analysis, with combined D0 and D28 samples from 49 cases and 129 controls (Figure 1), we 
confirmed our previous finding of TB risk associating with HLA-DR+CD4+, and reduced TB risk associating 
with BCG-specific IFN-γ, and anti–Ag85A IgG (Table 1). In addition, we found frequencies of HLA-DR+CD8+ 
T cells to be associated with TB risk (conditional logistic regression [CLR]; OR, 1.34; 95% CI, 1.08–1.67; P = 
0.008; FDR, 0.092) (Table 1). The magnitude of PPD-stimulated IFN-γ–expressing cells measured by ELISpot 
were also associated with reduced TB risk (OR, 0.71; 95% CI, 0.51–0.98; P = 0.037; FDR, 0.2) (Table 1).
We analyzed CMV-specific and EBV-specific IFN-γ ELISpot responses for evidence of  an association 
between viral infection and T cell activation in our infant cohort. Frequencies of  activated CD8+ T cells 
correlated with the magnitude of  the CMV-specific IFN-γ ELISpot response (Spearman’s rho, P = 6 × 10–8, 
Figure 2A), suggesting that CMV infection (as defined by a positive CMV-specific T cell response) is associ-
ated with CD8+ T cell activation in this infant cohort. A network representation of  positively correlating cell 
populations (26) (Spearman’s rho, P < 0.05) revealed 3 clusters dominated by activated CD8+ and activated 
CD4+ T cells with CMV-specific IFN-γ ELISpot response, CD3+ T cells with EBV-specific IFN-γ ELISpot 
response, and monocytes with B cells (Figure 2B).
Table 1. Conditional logistic regression of combined D0 plus D28 infant samples
Estimated OR of TB disease from a conditional logistic regression of D0 plus D28 immunological variable
Quantitative variable N Case Est ORA 95% CI P value FDR value AUROC
CD3+ T cell 329 88 0.98 0.75–1.28 0.86 0.94
CD4+ T cell 329 88 0.79 0.6–1.03 0.087 0.29
HLA-DR+ CD4 T cell 329 88 1.59 1.3–2 <0.0001 0.002 0.64
CD4+CD25+CD127– 329 88 0.84 0.62–1.12 0.23 0.59
CD8+ T cell 329 88 1.23 0.98–1.53 0.074 0.28
HLA-DR+ CD8+ T cell 329 88 1.34 1.08–1.67 0.008 0.092 0.59
CD14+CD16+ 329 88 0.93 0.73–1.18 0.57 0.82
CD14+CD16– 329 88 0.99 0.78–1.27 0.96 0.96
CD19+ B cell 328 88 1.13 0.87–1.4 0.39 0.69
BCG MGIA 146 50 0.82 0.52–1.29 0.39 0.69
85A ELISpot 324 91 0.87 0.63–1.2 0.39 0.69
BCG ELISpot 333 94 0.75 0.57–0.98 0.036 0.2 0.56
PPD ELISpot 270 79 0.71 0.51–0.98 0.037 0.2 0.57
TB10.3/10.4 ELISpot 270 79 0.96 0.74–1.23 0.72 0.83
EBV ELISpot 290 84 1.05 0.82–1.35 0.7 0.83
CMV ELISpot 319 91 1.01 0.8–1.23 0.9 0.94
FLU ELISpot 289 84 1.08 0.85–1.37 0.55 0.82
GAM.DEL (putative) 329 88 1.16 0.91–1.5 0.23 0.59
NK 16– (putative) 329 88 0.96 0.63–1.4 0.63 0.82
NK 16+ (putative) 329 88 0.86 0.66–1.12 0.26 0.6
CD14+CD16+/CD3+ 329 88 0.92 0.72–1.18 0.52 0.82
CD14+CD16–/CD3+ 329 88 0.96 0.74–1.22 0.68 0.83
Anti–Ag85A IgG 297 87 0.79 0.63–0.99 0.043 0.2 0.59
AUROC, area under the receiver operating characteristic; Estimated odds ratio, estimated OR. ARepresents the OR for a 1 unit change in the immune 
response. BCG, Bacille Calmette-Guérin; MGIA, mycobacterial growth inhibition assay; PPD, purified protein derivative; FLU, influenza; GAM.DEL, gamma 
delta T cells; NK 16, natural killer cells.
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Figure 2. CMV infection is associated with CD8+ T cell activation in South African infants. (A) Correlation matrix of significantly (Spearman’s rho, P < 
0.05) correlated cell populations and IFN-γ ELISpot responses to EBV and CMV using cellular data. The magnitude of the CMV-specific IFN-γ ELISpot 
response correlated with the frequency of activated CD8+ T cells. (B) Network of positively correlating cell populations using cellular data (Spearman’s 
rho, P < 0.05) showing 3 clusters dominated by activated T cells with CMV, CD3+ T cells with EBV, and monocytes with B cells (node color indicates 
cluster membership using clusters defined by ref. 26; red, clustering with CMV response; gray, clustering with EBV response; and yellow, clustering 
with myeloid cells). Red lines indicate between-cluster correlations, and black lines within-cluster correlations. Line width indicates the correlation 
coefficient. (C) Volcano plot using transcriptomic data showing magnitude and significance of differential expression between EBV+ and EBV– infants, 
where blue indicates genes that are downregulated in EBV+ infants and red indicates genes that are upregulated in EBV+ infants. (D) CMV–strongly pos-
itive (ELISpot > 100 SFC/million) and CMV– infants, where blue indicates genes that are downregulated in CMV+ infants and red indicates genes that 
are upregulated in CMV+ infants. Gray indicates genes for which expression is unchanged. The top 50 significant genes are labeled, and horizontal and 
vertical dashed lines indicate 20% FDR and 5% change in gene expression, respectively.
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EBV had a strong effect on the blood transcriptome, with 296 genes differentially expressed between infants 
with positive and negative EBV responses (Figure 2C). CCL8, CXCL10, and IFIT3 had the greatest fold 
increase in expression in EBV+ infants, indicating strong induction of a Type I/II IFN response, although we 
did not see a correlation between EBV ELISpot response and T cell activation in this study (Supplemental Table 
1; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.130090DS1).
The impact of  CMV on the blood transcriptome was smaller, with only 14 genes differentially expressed 
between CMV+ and CMV– infants (ELISpot > 17 spot-forming cells [SFC]/million), although there were 103 
differentially expressed transcripts between CMV–strongly positive (ELISpot > 100 SFC/million) and CMV– 
infants (Figure 2D and Supplemental Tables 2, A and B). Differentially expressed transcripts included HLA-
DRB1, ZNF683, LAG3, and KLRC2 (NKG2C). ZNF683 is an important paralog of  PRDM1 and, together 
with CCL5, has been shown to be highly induced in human CMV-specific CD8+ T cells when compared with 
naive CD8+ T cells (27). LAG3 is expressed on activated CD8+ and CD4+ T cells, and LAG3+CD8+ T cells are 
found in CMV infection (27, 28). NKG2C+ NK cells are expanded in response to CMV infection, although 
CMV infection can also induce the expression of  NKG2C on CD8+ T cells (29–31).
Expression levels of  transcripts from total peripheral blood mononuclear cells (PBMC) of  infants 
with a CMV ELISpot response (>100 SFC/million) were correlated with expression levels of  transcripts 
published from CD8+ T cells isolated from adults at different stages of  CMV infection (27). The highly 
significant correlation of  infant transcripts with CMV-specific CD8+ T cell transcripts from adults con-
firms the prominence of  an activated CD8+ T cell response in unstimulated PBMC of  CMV ELISpot–
positive infants (Supplemental Figure 1, A and B).
Our cellular data suggest that CMV IFN-γ responses are associated with activated HLA-DR+CD8+ 
T cells, and transcriptional analysis supports the presence of  an activated CD8+ T cell phenotype among 
total, unstimulated PBMC from CMV IFN-γ ELISpot–positive infants.
CMV antigen–specific T cell responses, measured up to 3 years prior to detection of  TB, associate with risk of  
TB disease in infants. CMV is associated with increased risk of  HIV infection and disease progression 
(12, 13, 15). To determine if  viral infection is associated with TB risk in our infant cohort, we analyzed 
CMV-specific and EBV-specific IFN-γ ELISpot responses in cases and controls. Infants dual-positive 
for both EBV and CMV (n = 3) were excluded from the analysis. When CMV status was treated as a 
binary variable, CMV positivity (defined as a CMV-specific IFN-γ ELISpot response > 17 SFC/million 
at either time point), measured up to 3 years prior to TB detection, was associated with increased risk 
of  TB disease (CLR; P = 0.043; OR, 2.22; 95% CI, 1.02–4.83) (Figure 3A). An ELISpot response to 
EBV alone was not associated with risk (Figure 3A), although a combined CMV and EBV response 
was associated with increased risk of  TB disease (CLR; P = 0.025; OR, 2.3; 95% CI, 1.11–4.79) (Fig-
ure 3B). To further explore this association, we analyzed time to TB diagnosis in TB cases. Infants with 
a positive CMV or CMV+/EBV+ ELISpot response developed TB earlier than negative infants (Log 
Rank Mantel-Cox, P = 0.037; Figure 3, C and D).
We analyzed data by vaccine group and saw no evidence that infants with positive CMV or CMV+/
EBV+ ELISpot responses who were immunized with MVA85A were at greater or lower risk of  TB disease 
when compared with infants with negative CMV ELISpot responses who were immunized with MVA85A 
(P = 0.8355 for CMV and P = 0.9177 for CMV/EBV).
Interestingly, there was almost no overlap in differentially expressed genes between CMV+ and EBV+ 
infants with only 7 genes significantly differentially expressed in both comparisons at an FDR of  20% 
(Supplemental Figure 2).
A CMV-specific IFN-γ response measured at 4–6 months of  age, up to 3 years before disease is detect-
ed, was a risk factor for the development of  TB disease in South African infants, and this risk was greatest 
during the first 10 months of  follow-up.
Transcriptional evidence of  activated T cells, Type I IFN responses, and NK cells in infants up to 3 years prior to 
detection of  TB. Because CMV ELISpot–positive infants were at greater risk of  disease, we stratified tran-
scriptome data by CMV status to identify transcripts able to classify case and control infants. When CMV+ 
and CMV– infants were analyzed together, 16 genes were significantly differentially expressed between 
cases and controls (Figure 4A and Supplemental Table 3). LAG3 and VCAM1, known markers of  T cell 
activation (28, 32, 33), had the greatest fold increase in expression in case infants. To test our ability to clas-
sify infants into cases or controls, we split samples randomly into a 70% training set and 30% test set and 
trained an artificial neural network. The process was repeated 50 times with random splits into training and 
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test set (bootstrapping), and area under the receiver operating characteristic (AUROC) and accuracy were 
recorded to assess predictive stability (Supplemental Figure 3A). When all infants were included in the 
analysis, we could classify infants into cases and controls with an average accuracy of  67% (AUROC, 0.77; 
95% CI, 0.69–0.85; Supplemental Figure 6A). Prediction accuracies were comparable when alternative, 
widely used classification algorithms were used (Supplemental Figure 3B).
In CMV+ healthy infants who developed TB in the following 3 years (cases), the NK cell–associat-
ed cytokine IL-32 and the NK cell–specific lectin-like receptors KLRC1 and KLRC3 were among tran-
scripts with the greatest decrease in fold-change of  expression and the highest predictive power (Figure 
4B, Supplemental Figure 4, and Supplemental Table 4). IL-32 enhances maturation of  monocytes to 
macrophages and has been shown to be important for protection against M.tb (34). In our cellular anal-
ysis, we observed decreased frequencies of  CD3–CD8–CD4– (triple negative) CD16– and CD16+ NK 
cells in infants who develop TB disease in the next 3 years when compared with CMV+ infants who do 
not develop disease (Supplemental Figure 6B).
In CMV– case infants, elevated expression of  T cell activation markers, including LAG3 and 
VCAM1; markers of  a Type I/II IFN response, including IFIT3; and enhanced expression of  a broad 
range of  both activated and inhibitory KIR receptors, including KIR2DL1, KIR2DL3, KIR2DL4, 
KIR2DL5A, KIR2DS3, KIR2DS5, KIR3DL1, and KIR3DL3, were observed (Figure 4C and Supple-
mental Table 5). Modular pathway analysis showed enrichment for NK and KIR cluster genes and a 
Type I/II IFN antiviral immune response in CMV– case infants when compared with controls (Figure 
4D). However, we saw no evidence of  increased NK cell frequency in infants who develop TB disease 
in our cellular analysis (Supplemental Figure 6B).
Figure 3. CMV+ infants are at increased risk of developing TB disease. (A) We saw a higher proportion of case (red) infants among CMV+ (n = 14 of 32) when 
compared with CMV– infants (n = 35 of 140), and there was no significant enrichment for cases among EBV+ infants (n = 3 of 7 compared with n = 46 of 163), 
although infants positive for either CMV or EBV (B) were at increased risk (n = 17 of 39 compared with 32 of 131). (C) CMV+ TB case infants (red triangles, n = 
14) developed TB disease earlier in follow-up when compared with CMV– infants (red circles, n = 35), and (D) TB case infants positive for either CMV or EBV 
(red triangles, n = 17) developed TB disease earlier than CMV–/EBV– infants (red circles, n = 32).
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Figure 4. Transcriptomic correlates of risk of TB disease are different in CMV+ and CMV– infants. Volcano plots showing magnitude and signifi-
cance of differential expression between all case and control infants (A), CMV+ case and control infants (B), and CMV– case and control infants (C). 
The top 50 significant genes are labeled, and horizontal and vertical dashed lines indicate 20% FDR and 5% change in gene expression, respective-
ly. Log2 FC color code: blue, downregulated in cases vs. controls; gray, unchanged; red, upregulated in cases vs. controls. (D) Enriched modules for 
differential expression in case and control infants among all, CMV+, and CMV– infants. Each row contains 1 module with the number of genes indi-
cated. Each significantly enriched module at a P < 0.05 is shown as a pie chart. The size of the pie corresponds to the AUROC in the cerno test, and 
intensity of the color corresponds to the enrichment q value. The red and blue color indicates the amount of significantly up- and downregulated 
genes, respectively, and gray color indicates the remaining nonsignificant genes within the category. The interaction term evaluates the statistical 
difference between changes in CMV+ and CMV– infants. (E and F) AUROC of the classification performance of the artificial neural network model, 
which was trained using approximately 70% of the data, and risk of TB was predicted on the withheld 30% of the data (Supplemental Figure 3A). 
The process was repeated 50 times with random splits into training and test set (bootstrapping), and the AUROC was recorded for each round for 
CMV+ (E) and CMV– (F) infants.
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TB risk–associated transcripts and immune pathways were different among CMV+ and CMV– infants, 
as highlighted by a modular pathway analysis, which uses an interaction term to compare pathways associ-
ated with TB risk among CMV+ and CMV– infants (Figure 4D and Supplemental Table 6).
When infants were stratified by CMV status, we were able to classify cases and controls within the 
CMV+ cohort with 92% average balanced accuracy and within the CMV– cohort with 89% average bal-
anced accuracy, with an average AUROC of  0.98 (95% CI, 0.96–1) and 0.9 (95% CI, 0.85–0.96), respective-
ly (Figure 4, E and F, and Supplemental Figure 5).
To validate the classifier signatures, we used raw data from an independent cohort of  10-week-old 
South African infants vaccinated with BCG at birth and unknown CMV status (NCBI’s Gene Expression 
Omnibus [GEO] database, GSE20716; ref. 5). Infants were enrolled into an efficacy trial of  intradermal or 
percutaneous delivery of  Japanese BCG at birth (3). A nested correlates of  risk study was performed using 
blood from 10-week-old healthy infants who developed TB disease within the following 2 years (5, 35). We 
sought to remove technical differences between the 2 array data sets to enable validation of  classifier signa-
tures (Supplemental Figure 7A); however, we could not fully normalize expression between the 2 data sets, 
most likely due to the age difference between infants in the 2 cohorts (2–3 months in GSE20716 and 4–6 
months in the MVA85A efficacy trial) (Supplemental Figure 7B). Despite these cohort differences and the 
loss of  more than half  of  the genes in our signature due to microarray platform differences, we were able to 
predict risk of  TB using our CMV– classifier with an accuracy of  63.9% and an AUROC of  0.71 (95% CI, 
0.63–0.79; Supplemental Figure 7C). Next, we attempted to improve accuracy by prediction and removal 
of  infants with suspected CMV infection. The number of  CMV+ infants with more than 1 predicted positive 
sample was low (n = 5, Supplemental Figure 7D) and excluding these infants led to a slight but not signif-
icant improvement in balanced accuracy of  65.6% and an AUROC of  0.74 (Supplemental Figure 7E). In 
all of  the analyses, we saw greater numbers of  differentially expressed genes when infants were stratified 
by CMV status. Many of  the immune pathways associated with risk in CMV– infants are in the opposite 
direction in CMV+ infants; therefore, these are canceled out when the 2 groups are combined.
Finally, we looked for enrichment of  transcripts from the 16–peripheral blood gene correlate of  risk 
(CoR) signature associated with progression to TB disease in M.tb–infected adolescents (36) among our 
CMV+ and CMV– infants. This adolescent CoR signature was significantly enriched among case infants 
when compared with controls, and the enrichment was strongest among CMV– infants (Supplemental Fig-
ure 8A). However, the adolescent CoR signature was not able to accurately classify infants into cases and 
controls (Supplemental Figure 8B). Including the CoR score in our infant network analysis, we show that 
the CoR score correlates with the frequency of  inflammatory monocytes and with our CMV– classifier 
signature (Supplemental Figure 8C). Our CMV+ classifier signature is positively correlated with T cell fre-
quency and negatively correlated with monocyte and CD16+ NK cell frequency.
A network representation of  positively correlating cell populations (Spearman’s rho, P < 0.05) revealed 
3 major clusters with the adolescent CoR and infant CMV– classifier signature clustering with inflammato-
ry and classical monocytes (Supplemental Figure 8D).
These findings further support distinct immunological correlates of  risk of  TB disease in CMV+ and 
CMV– infants. Taken together, our data show increased T cell activation, KIR receptor signaling, and Type 
I IFN response in CMV– case infants and decreased NK cell–associated transcripts in CMV+ case infants 
when compared with their respective controls. Furthermore, we identified transcriptomic signatures, which 
can identify infants with risk of  TB disease with high accuracy in CMV+ and CMV– infants, and we were 
able to validate the CMV– biomarker signature in an independent study with moderate accuracy.
T cell activation associates with lower mycobacterial antigen–specific immune response following immunization 
with MVA85A and BCG. To assess the impact of  T cell activation and CMV infection on the ability to 
mount an antigen-specific response following immunization with MVA85A, we examined mycobacterial 
antigen–specific IFN-γ responses and anti–Ag85A IgG in MVA85A-immunized infants at D28 following 
immunization with MVA85A. IFN-γ responses to Ag85A, measured on D28, were inversely correlated 
with activated CD4+ and CD8+ T cell frequencies (Figure 5, A and B). There was a trend toward lower 
mycobacterial antigen–specific IFN-γ responses and lower anti–Ag85A IgG in CMV+ when compared with 
CMV– infants (P = 0.058, Mann-Whitney U test), and anti–Ag85A IgG was inversely correlated with CMV 
ELISpot response in MVA85A immunized infants (Spearman’s rho, P = 0.026, Figure 5, C and D).
These data show that T cell activation and CMV infection influence MVA85A boosting of  an anti-
gen-specific immune response.
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Discussion
We demonstrate, in healthy infants, that CD8+ T cell activation and prior or subclinical infection with 
CMV (defined by a positive CMV-specific T cell response and treated as a binary variable) are associated 
with increased risk of  developing TB disease over the next 3 years of  life. We also show that CMV+ infants 
acquire TB disease earlier than CMV– infants. These data complement our previous finding that CD4+ T 
cell activation was associated with TB disease risk in infants and adolescents in a community with high 
TB incidence (6). CMV has been implicated in the etiology of  TB, supported by epidemiological asso-
ciations between the 2 diseases (21–25). In Gambian infants, CMV infection induced profound CD8+ T 
cell differentiation and activation, which persisted up to 2 years after infection (37, 38). Consistent with 
this effect, we show that infants with a positive T cell response to CMV peptides have a transcriptional 
signature associated with CMV-specific CD8+ T cells (27). However, among CMV+ infants, T cell activa-
tion markers were not differentially expressed between case and control infants, most likely because CMV 
itself  is a strong driver of  T cell activation, thus confounding the signature within this group.
In CMV+ infants, transcripts associated with NK cells had lower expression, and NK cell frequen-
cy was lower in cases when compared with controls. A role for NK cells in protection from TB disease 
has been demonstrated both in humans and animal models (39–45). The CD94 and NKG2C/KLRC2 
transcripts had among the greatest decreases in fold-change of  expression and the highest predictive 
power in identifying TB cases among CMV+ infants. KLRC2 deletion is associated with reduced num-
bers of  mature NK cells and increased susceptibility to HIV infection, certain autoimmune conditions, 
and cancer (46–49). We hypothesize that increased susceptibility to TB disease in CMV+ infants may 
result from loss of  control of  CMV replication and/or impairment of  NK cell function due to KLRC2 
gene deletions in some individuals (21).
Figure 5. T cell activation is associated with lower mycobacterial antigen–specific immune response following immunization with MVA85A. (A and B) 
The D28 IFN-γ ELISpot response to Ag85A was inversely correlated with both activated CD4+ T cell (A) and activated CD8+ T cell (B) frequency. (C) There 
was a trend for lower anti–Ag85A IgG in CMV+ compared with CMV– infants following immunization with MVA85A. (D) Anti–Ag85A IgG was inversely 
correlated with CMV ELISpot response. Mann Whitney U test and Spearman’s rho correlation. Red, cases; gray, controls.
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Among CMV– infants who went on to develop TB disease, we observed upregulation of  transcripts asso-
ciated with T cell activation, including LAG3 (28), which is induced during active TB in a nonhuman primate 
model (50). We also found multiple transcripts and pathways that are typically altered during viral infection 
among CMV– infants. This may be due to underestimation of  the prevalence of  viral infection, as we used 
only IFN-γ responsiveness to EBV and CMV CD8+ T cell epitopes as a measure of  viral infection. Detection 
of  viral DNA would allow more accurate diagnosis of  viral infection; however, this was not possible due to 
the very limited samples collected from these infants. Moreover, viruses or bacteria other than those measured 
in this study (i.e., CMV and EBV) may be contributing to risk of  TB disease among these infants. Expression 
of  a broad range of  both activating and inhibitory KIR receptor transcripts was elevated in CMV– case infants. 
Exposure to multiple viral infections drives high diversity of  KIR expression and lowers the availability of  
naive NK cells to respond to future infectious challenge, resulting in susceptibility to HIV (51, 52). We were 
able to identify different classifier signatures among CMV+ and CMV– infants and were able to verify our 
CMV– signature in an independent cohort of  infants (5). In the independent cohort, infants were younger 
(2–3 months of  age), and few infants were classified as CMV+. CMV infection and viral replication is low at 
birth, peaks at 3–6 months of  age, and declines to plateau at 8–10 months of  age (53). At 4–6 months of  age, 
infants recruited in to the MVA85A efficacy trial (4) were at the peak age of  CMV viral replication in infancy.
Our transcriptional evidence of  immune activation in infants who develop TB disease is consistent with 
the observations of  Zak et al. (36), who reported increased expression of  Type I/II IFN–associated tran-
scripts in M.tb–infected adolescents who progressed to TB disease. Increased Type I/II IFN transcripts have 
also been observed in patients with active TB disease, when compared with M.tb–infected or –uninfected 
controls (54–58). Recent data from the M.tb–infected adolescent study has shown that an increased Type I/
II IFN response precedes a shift toward an elevated monocyte/lymphocyte ratio and an increase in T cell 
activation, which are detected closer to the time of  TB disease (59). The authors suggest that the initial ele-
vation in Type I/II IFN could be driven by viral infection and that this could then trigger the immune events 
that lead to TB susceptibility (59). Consistent with this, we found a correlation of  the adolescent CoR score 
with an EBV-specific T cell response and with elevated CD14+CD16+ inflammatory cells. We also observed 
significant enrichment of  the 16-gene CoR signature identified by Zak et al. among our CMV– case infants 
(36). However, the CoR signature was not able to accurately classify case and control infants. In our study, 
the infants were not infected with M.tb, had no symptoms of  TB disease, and had no known exposure to TB 
in the household during enrollment or when the blood samples were obtained. In addition, since incident TB 
disease was diagnosed months to years after blood sample collection, it is unlikely that the elevated Type I/
II IFN–associated transcriptomic signatures we observed are a result of  subclinical TB disease.
One limitation of  this study is the small number of  CMV+ infants (n = 18); the potential association 
between CMV infection and risk of  TB disease now requires validation in a larger cohort with adjustment 
for known confounders, such as TB exposure and socioeconomic status, although socioeconomic status is 
known to be largely homogeneous in this particular population in the Western Cape (60). Samples were not 
available for serological analysis; therefore, CMV-specific T cell responses were measured as an indicator 
of  CMV infection. However, CMV-specific IFN-γ responses have been shown to correlate with antibody 
responses (61, 62), and CMV-ELISpot and QuantiFERON assays are available and perform well as diag-
nostic tests for CMV infection and CMV DNA viremia (63). Furthermore, using cellular immunity as a 
marker of  infection allows differentiation of  young children with prior exposure to CMV from those with 
passive maternal antibody (62, 64). Although consistent with the etiology of  CMV infection in infants, we 
are unable to confirm that immune activation was chronic, as only 2 samples were collected 4 weeks apart, 
and it is possible that T cell activation could have been driven by acute infection in some cases. While 
only CMV and EBV were measured in this study, other infections may also contribute to T cell activation, 
and CMV may be acquired or activated as a result of  comorbidities, including respiratory or diarrheal 
infections. However, blood sampling at time of  enrollment and a stringent screening process ensured that 
any infant with sign or symptom of  coinfection was excluded from the study. Safety bloods and frequent 
follow-up showed no clinical indication of  active infection.
All infants in this study received BCG at birth, and the T cell response to BCG peaks at 2–3 months 
of  age (65). Viral infections during the development of  the BCG-specific immune response may impair 
the development of  protective immunity, as has been suggested by studies in Malawi (66). In the Gam-
bia, exposure to HIV in utero and being born in the wet season, associated with increased respiratory 
and diarrheal disease, have been shown to impact the BCG antigen–specific T cell response following 
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vaccination (37, 67). We observed an inverse correlation between CD4+ and CD8+ T cell activation 
and antigen-specific T cell responses following immunization with MVA85A, suggesting that T cell 
activation may be associated with decreased vaccine boosting in infants. This confirms previous obser-
vations where increased immune activation was associated with lower immune responses to MVA85A 
in both infants and adults (68, 69). It could also explain why immune responses to MVA85A were lower 
when administered within a week of  vaccination with DTwP-Hib and hepatitis B in the Expanded Pro-
gramme on Immunization (EPI) schedule (70).
Childhood TB is difficult to diagnose and treat, and improved strategies are needed to control TB in 
children (71). We found that a CMV-specific IFN-γ response was associated with increased risk of  devel-
oping TB disease in infants and that distinct immune pathways were associated with TB disease risk in 
CMV+ and CMV– infants. We suggest that viral infection may increase the risk of  progression to TB disease 
and may compromise the immune response to TB vaccines given in infancy. Strategies to reduce chronic 
viral infections such as the use of  vaccines or antivirals, and protective behaviors including handwashing 
and glove use, are particularly important during pregnancy to reduce to frequency of  congenital infection 
(72–75). Such interventions may have broader benefits in enhancing TB vaccine efficacy, reducing TB risk, 
and helping to reduce the global burden of  childhood TB.
Methods
Case-control design. Infants who were enrolled in an efficacy trial of  the candidate TB vaccine MVA85A were 
included in this study (ClinicalTrials.gov, NCT00953927; ref. 4) (Figure 1). All infants received BCG within 7 
days of  birth. Infants were screened at 4–6 months of  age, and only those with clinical parameters within the 
normal range who were HIV- and M.tb–uninfected infants and without known TB exposure were included 
in the trial. CMV and EBV analysis was conducted on a blood sample taken at this time point. Infants were 
randomized at 16–24 weeks of  age to receive a single intradermal dose of  MVA85A or placebo (Candin, a 
candida skin test antigen; AllerMed) (4). Transcriptomic analysis was performed using PBMC from infants 
who were included in our previously described case-control study (6). Briefly, infants who met the primary 
case definition for TB disease (Supplemental Table 7) were included as cases. Infants developed TB disease at 
a mean of  15 months (1–32 months) after baseline blood draw. For each case, 3 infants were randomly select-
ed from a pool of  controls (Figure 1). Infants were included in the control pool if  they did not demonstrate 
M.tb infection as defined by a positive QuantiFERON TB Gold In-tube test (Cellestis); had not received TB 
treatment; and had not received isozianid preventive therapy during study follow-up. Matching was based on 
sex, ethnic group, CDC weight-for-age percentile (± 10 points), and time on study (± 9 months).
Infant PBMC samples collected from 2 time points, D0 and D28, were combined for testing of  both cel-
lular parameters and transcriptional signatures associated with risk of  TB disease. Only infants for whom 
a sample was available at both D0 and D28 were included in the analysis, resulting in a combined analysis 
of  a maximum of  98 samples from 49 cases and 258 samples from 129 controls (actual numbers in analysis 
vary per availability of  assay data and are listed in Table 1 and Figure 1).
The demographic and clinical characteristics of  CMV+ vs. CMV– infants are summarized in Supple-
mental Table 8 and were similar between groups. Socioeconomic status is known to be largely homoge-
neous in this particular population in the Western Cape.
Cell culture. PBMC were retrieved from liquid nitrogen storage, thawed, and rested for 2 hours in media 
containing DNase (Merck Chemicals Ltd.) to aid the removal of  debris from dead and dying cells. After 
2 hours, cells were counted and immediately transferred to cell culture plates for stimulation for RNA 
extraction, ELISpot assays, or measurement of  cell-surface markers assessed by flow cytometry. Viability of  
thawed PBMC was assessed using flow cytometry with Live/Dead Violet stain (Invitrogen). Phytohemagglu-
tinin (PHA) was included as a positive control for cell viability on ELISpot plates.
RNA processing. Rested PBMC (1 × 106) were resuspended in single wells of  200 μL RPMI (Sigma) 
supplemented with 10% FBS (Biosera) and L-glutamine (Sigma). Cells were stimulated for 12 hours 
at 37°C in single wells containing live BCG solvent for suspension for injection (SSI) from pooled 
vaccine vials (approximately 2 × 105 CFU/mL). After 12 hours of  stimulation, cells were pelleted and 
lysed in RNA lysis buffer (RLT, Qiagen). RNA was extracted using the RNeasy Mini Kit (Qiagen) per 
the manufacturer’s instructions with the following modification; in the first step, an equal volume of  
80% ethanol was added to cells lysed in RLT buffer, mixed, and total volume transferred to an RNeasy 
column. RNA was quantified by NanoDrop (Thermo Fisher Scientific) and stored at –80°C until use. 
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Extracted RNA was amplified and labeled with biotin using the Illumina Total Prep kit (Ambion) per 
manufacturer’s instructions. Amplified RNA was assessed by NanoDrop and Bioanalyzer for quantity 
and quality prior to hybridization. Hybridization to Illumina HT-12 arrays was performed per manu-
facturer’s instructions. Arrays were scanned using an Illumina iScan machine, and data were extracted 
using Genome Studio software.
Ex vivo IFN-γ ELISpot assay. The ex vivo IFN-γ ELISpot assay was performed as previously described 
using a human IFN-γ ELISpot kit (capture mAb 1-D1K) (Mabtech) (6). Briefly, duplicate wells contain-
ing 3 × 105 PBMC were stimulated for 18 hours with antigen, PHA (Sigma), or media alone. Antigens 
included a single pool of  Ag85A peptides (2 μg/mL/peptide; Peptide Protein Research); BCG (2 × 105 
CFU/mL; Statens Serum Institute); purified protein derivative (PPD) from M.tb (20 μg/mL; Statens 
Serum Institute); and peptide pools containing known CD8+ T cell epitopes from EBV (15 peptides) and 
CMV (5 peptides) (2 μg/mL/peptide, AnaSPEC). Results are reported as SFC per million PBMC, calcu-
lated by subtracting the mean of  the unstimulated wells from the mean of  antigen wells and correcting 
for the number of  PBMC. A response was considered positive if  the mean number of  spots in the antigen 
well was at least twice the mean of  the unstimulated wells and at least 5 spots greater.
Cell surface flow cytometry. As previously described (6), PBMC were washed and stained with 5 
μL Live/Dead Violet (Invitrogen) followed by surface staining with the following titrated antibodies: 
0.5 μL CD3-AF700 (clone UCHT1, eBioscience), 2 μL CD4-APC (clone RPA-T4, BioLegend), 2 μL 
CD8-eFluor605 (clone RPA-T8, eBioscience), 2 μL CD14-PE/Cy7 (clone HCD14, BioLegend), 2 μL 
CD16-AF488 (clone 3G8, BioLegend), 1 μL CD19-PE/Cy5 (clone HIB19, BioLegend), 2 μL CD25-
APC/Cy7 (clone BC96, BioLegend), 2 μL CD127-NC650 (clone eBioRDR5, eBioscience), and 15 μL 
HLA-DR–PE (clone L243, BioLegend). Fluorescence minus one (FMO) controls were used to set gates 
for CD25, CD127, and HLA-DR. Samples were acquired on a BD LSR II flow cytometer. Results are 
presented as percentages of  cells after excluding dead cells and doublets. CD4+ and CD8+ T cells were 
identified as CD3+ cells, while CD14+/− and CD16+/− cells were identified as CD3− and CD19− popu-
lations. CD25+CD27− populations were gated on the CD4+ cells. The network representation of  cell 
populations positively correlated among all infants was done using the igraph package in R. To iden-
tify closely related clusters (communities) within the network, the cluster_optimal function was used, 
implementing an algorithm described in Brandes et. al.(26).
Transcriptional analysis. Raw, probe level summary values exported from Illumina GenomeStudio 2011 
of  Illumina HumanHT 12 V4 microarrays were imported into R using BeadArray (76). Probes were back-
ground corrected using negative control probes followed by quantile normalization using the neqc com-
mand (77). The analysis was restricted to probes with a detection P < 0.01 in at least 10% of  the samples 
and probes matching to the transcript definition of  the following databases (in descending importance) 
with at most 2 mismatches, no insertions, and a minimum mapping length of  40 bases: GENCODE ver-
sion 23, RefSeq (refMrna.fa), and GenBank (mrna.fa) downloaded in August 2015 from http://hgdown-
load.cse.ucsc.edu/goldenPath/hg38/bigZips/.
A linear model was fitted using limma (78) to determine differential expression adjusted for vaccine, 
day, stimulus, sex, age, ethnicity, and batch effects. Array quality weights were incorporated (79) to account 
for between-array quality differences. To account for between-patient correlations, the duplicateCorrelation 
command from the limma package was used. Nominal P values were corrected for multiple hypotheses test-
ing using the Benjamini-Hochberg procedure (80). Due to the heterogeneity of  the samples, a lenient cut off  
at an FDR of  20% was chosen to identify genes as significantly differentially expressed. In total, 221, 101, 
and 16 probes mapping to 203, 95, and 16 genes were significantly differentially expressed between case and 
control infants within CMV–, CMV+, and the combined group, respectively. For the comparison of  EBV+ vs. 
EBV–, CMV+ vs. CMV–, and CMV–strongly positive (ELISpot > 100 SFC/million) vs. CMV–, in total, 334, 
14, and 103 probes mapping to 296, 14, and 97 genes were significantly differentially expressed, respectively.
Pathway analysis, performed using gene set enrichment analysis (GSEA), was carried out using the 
cerno test from the tmod package in R. Modules for the enrichment analysis were taken from Li et al. (81). 
Data sets used for comparative analysis to CMV-infected CD8+ T cells were obtained from GEO by down-
loading GSE12589 and GSE24151.
Classification. For classification into cases and control samples, we used normalized microarray inten-
sities adjusted for scan date, sample collection time point (D0 or D28), and stimulation (unstimulated or 
BCG stimulated). Features for training were selected by using the significant probes at 20% FDR and select-
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ing only the probe with the highest average expression per gene, giving the final transcriptional signature 
size of  95, 203, and 16 genes for CMV+, CMV–, and all infants, respectively. Each infant was represented 
either by sets of  2 samples (unstimulated and BCG stimulated either at D0 or D28) or by sets of  4 samples 
(unstimulated or BCG stimulated at D0 and D28). To avoid overfitting, we implemented a modified nested 
cross-validation scheme such that only complete sample sets per infant were assigned to either test or train-
ing set at each splitting iteration during the cross-validation process.
Model training was performed using a neural network model as implemented in the nnet package 
through the caret interface in R (82). In the outer loop, samples were split 50 times with replacement into 
training (about 70%) and test sets (about 30%) to evaluate model performance and feature importance. For 
model parameter tuning in the inner loop, each training set was split into training and validation sets using 
a leave-1-infant-out cross validation scheme, and the AUROC was recorded as performance metric over a 
grid of  4 size and 4 decay parameter combinations. All accuracies stated in the manuscript are provided 
as balanced accuracies (83) to account for the imbalance of  the case and control infants within our cohort.
To validate our classification results, an independent cohort of  10-week-old South African infants vac-
cinated with BCG at birth was obtained as raw expression data from GEO by downloading GSE20716. 
Study batch was removed with the ComBat command in R using parametric adjustment, risk of  TB as null 
model, and the validation cohort as reference in order to avoid any bias on the validation cohort. For pre-
diction of  risk of  TB, 112, 50, and 5 probes overlapped between Illumina HumanHT 12 V4 and Illumina 
HumanRef-8 V2 for within CMV–, CMV+, and the combined group, respectively. CMV status prediction 
was performed using 55 overlapping probes, which were differentially expressed between CMV– and CMV–
strongly positive (ELISpot > 100 SFC/million) infants at an FDR of  20%. Only infants with at least 2 
positive samples were labeled as suspected CMV+.
Data availability. Raw and normalized expression data have been deposited at GEO under the accession 
number GSE98550.
Statistics. Data were analyzed using R. CLR was conducted to identify associations between cellular immune 
parameters or CMV and/or EBV IFN-γ ELISpot responses and risk of TB disease. Correlations between 2 mea-
sures were performed using Spearman’s rho. A log-rank Mantel-Cox test was used to determine whether infants 
with a positive CMV and/or EBV IFN-γ ELISpot response developed TB earlier than negative infants.
Study approval. Samples used in this study were taken from an efficacy trial of  the candidate TB vaccine 
MVA85A (ClinicalTrials.gov, NCT00953927; ref. 4) (Figure 1). This trial was approved by the University 
of  Cape Town Faculty of  Health Sciences Human Research Ethics Committee, Oxford University Tropical 
Research Ethics Committee, and the Medicines Control Council of  South Africa.
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